Griffeth Tully

Embolic Protection, Inc. develops proprietary filters that capture embolic material that is dislodged during cardiovascular surgery.

Velomedix is a development stage medical device company created to realize the clinical potential of mild therapeutic hypothermia in benefiting patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury. A comprehensive review of the medical literature demonstrates that cooling protects cells at risk, prevents tissue death and preserves organ function. Therapeutic Hypothermia offers a novel solution for the protection of the body's organs during ischemic insults and later from reperfusion injury. Cooling protects tissue during ischemia by reducing oxygen metabolism, inflammation and maintaining cell membrane integrity. In the case of reperfusion injury hypothermia reduces oxidative stress, micro vascular clogging, free radical production and inflammatory responses which are destructive to cells that have had blood flow restored after a period of ischemia.

CardioKinetix, Inc. develops ventricular partitioning device for heart failure disease. It develops transcatheter implant called the Parachute Ventricular Partitioning Device, which intends to treat heart failure resulting from a heart attack in patients by improving overall cardiac function. The company was founded by Alexander Khairkhahan, Serjan D. Nikolic and Hugh R. Sharkey in 2002 and is headquartered in Menlo Park, CA.

Breathometer, Inc. designs a breathalyzer to determine the blood alcohol into the body. It provides its products under the categories of fitness and sports accessories, health and biotech accessories, biometrics, health and biotech, lifestyle, sensors, wearables and wireless devices. The company was founded by Charles Michael Yim in September 2012 and is headquartered in Burlingame, CA.